Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 8/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217003 | 0.97 | POLB (0.43) | TP53SMN1; SMN2POLBMAPTPIK3C3 | |
| SCHEMBL5221904 | 0.89 | ACMSD (0.33) | TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL5217014 | 0.86 | HDAC1 (0.34) | SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL1583553 | 0.83 | TP53 (0.52) | TP53SMN1; SMN2POLBMAPTPIK3C3 | |
| SCHEMBL475737 | 0.79 | POLB (0.55) | TP53SMN1; SMN2POLBMAPTPIK3C3 | |
| SCHEMBL18767065 | 0.78 | POLB (0.54) | TP53SMN1; SMN2POLBMAPTPIK3C3 | |
| SCHEMBL5901042 | 0.78 | TP53 (0.48) | TP53SMN1; SMN2POLBMAPTALDH1A1 | |
| SCHEMBL5223898 | 0.78 | MEN1 (0.44) | SMN1; SMN2POLBMAPTALDH1A1 | |
| SCHEMBL5222204 | 0.77 | TP53 (0.47) | TP53SMN1; SMN2POLBMAPTPIK3C3 | |
| SCHEMBL5225022 | 0.77 | TP53 (0.47) | TP53SMN1; SMN2POLBMAPTPIK3C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | TP53 3868/4885SMN1; SMN2 478/4885POLB 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.